chartexchange

Tempest Therapeutics Exercises Option to License Senlang’s CD7-Targeted Lentiviral In Vivo CAR-T Platform Following Initial Phase 1 Results with Lead BCMA/GPRC5D Candidate

GlobeNewswire Inc. | Nov 11, 2026 8:53 AM EST

-Tempest secures exclusive global rights outside China to a targeted lentiviral platform and portfolio of  in vivo CAR-T candidates

Read original article